These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12429815)

  • 1. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.
    Stoehr R; Knuechel R; Boecker J; Blaszyk H; Schmitt R; Filbeck T; Hofstaedter F; Hartmann A
    Lab Invest; 2002 Nov; 82(11):1553-61. PubMed ID: 12429815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
    Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
    Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract.
    Hafner C; Knuechel R; Zanardo L; Dietmaier W; Blaszyk H; Cheville J; Hofstaedter F; Hartmann A
    Oncogene; 2001 Aug; 20(35):4910-5. PubMed ID: 11521204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis.
    Hartmann A; Rösner U; Schlake G; Dietmaier W; Zaak D; Hofstaedter F; Knuechel R
    Lab Invest; 2000 May; 80(5):709-18. PubMed ID: 10830781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
    BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
    Stoehr R; Zietz S; Burger M; Filbeck T; Denzinger S; Obermann EC; Hammerschmied C; Wieland WF; Knuechel R; Hartmann A
    Eur Urol; 2005 Jan; 47(1):58-63. PubMed ID: 15582250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
    Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
    Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.
    Yamamoto S; Tada M; Lee CC; Masuda C; Wanibuchi H; Yoshimura R; Wada S; Yamamoto K; Kishimoto T; Fukushima S
    Jpn J Cancer Res; 2000 Feb; 91(2):181-9. PubMed ID: 10761705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular evidence supporting field effect in urothelial carcinogenesis.
    Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
    Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of p53 mutations in bladder washings and histologic specimens.
    Vet JA; Hessels D; Marras SA; van de Kaa CA; van der Poel HG; Michalides RJ; Debruyne FM; Schalken JA
    Am J Clin Pathol; 1998 Nov; 110(5):647-52. PubMed ID: 9802351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
    Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
    Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
    Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
    Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
    Sun W; Zhang PL; Herrera GA
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.